Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT05986045

ENHANCE- Establishing Natural History in an Advanced New CF Care Era

Measured outcomes for people with CF have improved dramatically over the last 20 years, even prior to the widespread introduction of cystic fibrosis transmembrane conductance regulator (CTFR) modulator treatments. The outlook for children with CF has improved significantly, with longer predicted survival and a lower likelihood of morbidity. This has accelerated recently. These changes have occurred within a short period of time, and there is much that we now do not understand about disease progression in children with CF and how this differs from children without CF. CF is an area which is fortunate to have well-developed and successful disease registries. CF registries have provided significant amounts of very useful data to guide improvement in treatment and outcomes over many decades. The power of registries comes from the collection of a well-defined set of important outcome measures in very large numbers of people over many years.

The outcome measures collected routinely in clinical care, which form part of the registries, are helpful in monitoring moderate-advances and symptomatic disease in people with CF. CF registries however do not tend to collect tomography(CT) scores, lung clearance index(LCI) or indeed repeated collection of biomarkers of disease activity such as sweat chloride which are increasingly relevant in an era of modulator therapies and reducing burden of symptomatic disease. We perceive an urgent need to complement registry data, cataloguing the changing natural history if early childhood CF by proactively collecting and curating sensitive, meaningful outcome data in a large cohort of children during this new era in Ireland and the UK.

The prevalence, presentation and natural history of disease manifestation of CF in young children will change significantly in the next decade with advances in the understanding and treatment of CF, including the use of therapies aimed at CFTR function. ENHANCE provides an opportunity to study these changes in real-time and in ways that are relevant to the CF community.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Cystic Fibrosis Congenital, Hereditary, and Neonatal Diseases and Abnormalities Digestive System Diseases Genetic Diseases, Inborn Infant, Newborn, Diseases Lung Diseases Pancreatic Diseases Respiratory Tract Diseases

Age range

1 month–5 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Children with CF attending one of the study centres and fulling one of the following:

  • Newborn infant diagnoses with cystic fibrosis through newborn screening (excludes children with an uncertain diagnosis), or having 2 documented CF disease causing mutations.
  • Children with CF (sweat chloride>60mmol/L or 2 CF disease causing mutations) aged 0-6 at study initiation
  • Healthy control infants without CF

Exclusion criteria

  • Children or their parents not willing or able to complete with study procedures or assessments.
  • Co-morbidities in groups 1 and 2, unrelated to CF, that in the opinion of the investigator would substantially impact on study measurements and unduly affect the veracity of the outcome data, for example a diagnosis of inflammatory bowel disease or extreme prematurity.
  • Children in the control group who are carriers of CFTR mutations or have chronic medical or GI/Liver conditions that in the opinion of the investigator would unduly affect the veracity of the outcome data.
  • We will not exclude someone who subsequently joins a CF Investigational drug trial if they are happy to continue, but if possible, will time their annual ENHANCE data collection to fall outside the time period of any experimental study drug administration

Treatment and study plan

Quality of life

Other

ENHANCE will collect natural history on all children with cystic fibrosis who are enrolled over a 5 year period

Primary outcomes

  1. 1. The incidence, prevalence and progression of structural lung disease

    Time frame: 60 Months

    Spirometry-controlled Computed Tomography

  2. 2. The long-term natural history of pulmonary function and ventilation homogeneity.

    Time frame: 60 Months

    Spirometry, Multiple Breath Washout

  3. 3. The incidence, prevalence and longitudinal progression of CF liver disease.

    Time frame: 60 Months

    Liver Ultrasound, Liver Function Tests

  4. 4. The prevalence, natural history and progression of exocrine pancreatic dysfunction

    Time frame: 60 Months

    Faecal Elastase Analysis

  5. 5. The longitudinal natural history of gastrointestinal symptoms, inflammation and the gut microbiome compared to a healthy control population

    Time frame: 60 Months

    Microbiome Analysis, Identification of inflammatory markers, Abdominal Symptom Scores

  6. 6. The longitudinal natural history of annual sweat chloride levels in infants and children of different ages, the influence of different treatments on this and its association with other outcomes

    Time frame: 60 Months

    Sweat chloride

  7. 7. The longitudinal natural history of mental health outcomes in children with CF compared to controls.

    Time frame: 60 Months

    Mental Health Quality Of Life Questionnaires

Study contacts

Contact information is provided by the study sponsor or research team.

Karen Lester, PhD

CONTACT

[email protected]

(01) 4096500

Rachel Cregan, MSc

CONTACT

[email protected]

(01) 4096500

Sponsors and collaborators

Lead sponsor

Royal College of Surgeons, Ireland

Other

Collaborators

  • Alder Hey Children's NHS Foundation Trust
  • Belfast Health and Social Care Trust
  • Cardiff and Vale University Health Board
  • Cork University Hospital
  • Erasmus University Rotterdam
  • Manchester University NHS Foundation Trust
  • Massachusetts General Hospital
  • Medizinische Hochschule Brandenburg Theodor Fontane
  • NHS Lothian
  • Newcastle-upon-Tyne Hospitals NHS Trust
  • Royal Brompton & Harefield NHS Foundation Trust
  • Teagasc
  • The Hospital for Sick Children
  • University College Hospital Galway
  • University Hospital of Limerick

Registry information

Official study title

Establishing Natural History in an Advanced New CF Care Era

Important dates

Study start
2023
Primary completion
2028
Study completion
2028
First posted
Aug 14, 2023
Registry last updated
Aug 31, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.